https://scholars.lib.ntu.edu.tw/handle/123456789/568505
標題: | Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B | 作者: | Pan C.J.-H. Wu H.-L. Kuo S.F.-T. JIA-HORNG KAO TAI-CHUNG TSENG CHEN-HUA LIU PEI-JER CHEN CHUN-JEN LIU DING-SHINN CHEN |
公開日期: | 2012 | 出版社: | Springer New York LLC | 卷: | 6 | 期: | 3 | 起(迄)頁: | 591-597 | 來源出版物: | Hepatology International | 摘要: | Purpose Acute exacerbation (AE) of chronic hepatitis B virus (HBV) infection is common and negatively impacts the clinical outcome. Factors predicting outcomes after exacerbations were only partly clarified. We investigated the host immune parameters associated with long-term outcomes. Methods We prospectively examined the profiles of serum cytokines and chemokines in 36 consecutive hepatitis B e antigen (HBeAg)-positive patients (male 72%, age 40.8 ± 9.9 years, genotype B/C 75%/25%) who developed AE in a medical center. The patients were followed up for a median of 4 years (range 2-6 years) post-AE. The impact of six cytokines (tumor necrosis factor alfa, interferon gamma, IL-2, IL-4, IL-6, and IL-10) and five chemokines (CXCL10/IP-10, CCL2/MCP-1, CXCL9/MIG, CCL5/ RANTES, and CXCL8/IL-8) at the onset of AE activity on the long-term outcomes were analyzed. Results Of 36 patients, 22 (61.1%) developed HBeAg seroconversion during follow-up (Group I), and the remaining 14 patients did not obtain HBeAg seroconversion (Group II). Baseline characteristics were generally similar between two groups of patients. In Group I patients, the frequency of undetectable serum IL-6 level (<3 pg/mL) at the onset of AE was significantly higher in comparison with Group II patients in multivariate analysis (86.4 vs. 42.9%, P = 0.016). Conclusions Our findings indicate that undetectable serum IL-6 level at the early stage of AE correlated with the longterm outcomes and may serve as a useful clinical predictor. ? Asian Pacific Association for the Study of the Liver 2011. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984562881&doi=10.1007%2fs12072-011-9299-2&partnerID=40&md5=f1f113dc903da90bb55fbb204dee50fa https://scholars.lib.ntu.edu.tw/handle/123456789/568505 |
ISSN: | 1936-0533 | DOI: | 10.1007/s12072-011-9299-2 | SDG/關鍵字: | CXCL9 chemokine; gamma interferon; gamma interferon inducible protein 10; hepatitis B(e) antigen; interleukin 10; interleukin 2; interleukin 4; interleukin 6; interleukin 8; lamivudine; monocyte chemotactic protein 1; RANTES; tumor necrosis factor alpha; virus DNA; adult; article; cytokine response; disease exacerbation; disease severity; female; follow up; genotype; hepatitis B; Hepatitis B virus; human; male; outcome assessment; priority journal; prognosis; prospective study; protein blood level; remission; seroconversion |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。